Precision Fermentation Powers Nationwide Egg Alternative Expansion
November 5, 2025, 9:39 pm
Location: United States, California, Sunnyvale
Employees: 10001+
Founded date: 1962
Total raised: $350M
EVERY Company secures $55 million in Series D funding. This capital propels nationwide expansion for its animal-free egg proteins. Precision fermentation offers a stable, sustainable alternative to traditional eggs. Products launch this month in Walmart stores across the US. This move targets mass-market adoption. The company addresses global food system fragility, volatile egg supply chains, and avian flu risks. It enhances protein accessibility and cost-efficiency for manufacturers in bakery, beverage, and protein sectors. This investment signals a major shift in biomanufacturing's role in future food production.
The EVERY Company leads a revolution in food technology. It recently closed a $55 million Series D funding round. This significant capital influx fuels its ambitious growth plans. The company aims for nationwide expansion. It will scale production of its innovative animal-free egg proteins.
McWin Capital Partners led the funding. Other investors joined the round. Main Sequence, Bloom8, and Minerva Foods participated. TO.VC, Grosvenor Food & Ag, and New Agrarian also invested. SOSV, Grupo Bimbo, Grupo Nutresa, and even celebrity Anne Hathaway back the venture. This diverse investor base highlights broad confidence in EVERY's vision.
The investment targets several key areas. It will boost manufacturing capacity. It aims to accelerate the company's path to profitability. The funding will drive mass-market adoption. This includes both retail and foodservice channels.
EVERY's core innovation lies in precision fermentation. This advanced biomanufacturing process creates proteins. These proteins replicate traditional egg functionality. They offer a direct alternative to conventional eggs. The technology decouples protein production from animal agriculture. This provides a more sustainable and resilient food source.
The company's products offer critical advantages. They are animal-free. They are cage-free compliant. They eliminate exposure to livestock-related risks. Traditional egg production faces numerous vulnerabilities. These include disease outbreaks like avian flu. Volatile feed prices also create instability. Environmental concerns add to the pressure. EVERY's approach provides a robust solution.
A major milestone looms this month. EVERY Company proteins will launch in Walmart stores across the United States. This marks a pivotal moment. It shifts the company from niche offerings to mass-market availability. Walmart's vast distribution network offers unparalleled reach. This partnership will introduce animal-free egg proteins to millions of consumers.
EVERY’s product lineup includes OvoPro™ and OvoBoost™. OvoPro™ functions as a direct substitute for egg whites. OvoBoost™ is a neutral protein. It fortifies various food and beverage applications. These proteins are versatile. They integrate into baked goods, beverages, and protein supplements. Their applications span wide.
The proteins are available in powder form. This enhances logistical efficiency. They are shelf-stable for up to 18 months. This eliminates the need for refrigeration. It significantly reduces cold chain costs for manufacturers. This benefit is crucial for high-volume sectors like bakeries. Traditional liquid eggs demand costly cold storage and transport.
The global egg market is substantial. It represents $270 billion. EVERY seeks to secure a significant share. Its technology offers equivalent or superior functionality. It does so without the inherent risks of traditional supply chains. The company already produces metric tons of product monthly. It aims to meet demand from the world's largest food companies.
Food producers increasingly grapple with instability. Volatile egg prices are a constant challenge. Fragile supply chains often break down. Avian flu outbreaks devastate poultry populations. These factors highlight the urgent need for alternatives. EVERY provides a stable and reliable protein source. It frees producers from these systemic risks.
The company's technology is a game-changer. It offers functional, scalable solutions. It delivers large quantities of egg protein at commercial scale. This reassures food companies. They gain a reliable option for supply chain challenges. This demonstrates biomanufacturing's potential to transform the entire food industry.
EVERY's headquarters are in San Francisco. Its products are FDA-approved. This regulatory clearance underpins consumer trust. It also ensures broad market acceptance. The company is not just conceptualizing new ideas. It is delivering concrete, scalable solutions.
The investment supports increased production capacity. This is vital for the Walmart rollout. It ensures the company can meet soaring demand. Consumer interest in alternative proteins continues to rise. This trend is driven by health, ethical, and environmental considerations. EVERY is positioned to capitalize on this growing market.
Biomanufacturing is maturing rapidly. It is becoming a resilient, scalable part of the global food supply chain. EVERY Company stands at the forefront of this evolution. Its progress validates the sector's potential. It proves that next-generation food production is here. The future of food involves less reliance on animals. It embraces scientific innovation. EVERY leads this charge.
The EVERY Company leads a revolution in food technology. It recently closed a $55 million Series D funding round. This significant capital influx fuels its ambitious growth plans. The company aims for nationwide expansion. It will scale production of its innovative animal-free egg proteins.
McWin Capital Partners led the funding. Other investors joined the round. Main Sequence, Bloom8, and Minerva Foods participated. TO.VC, Grosvenor Food & Ag, and New Agrarian also invested. SOSV, Grupo Bimbo, Grupo Nutresa, and even celebrity Anne Hathaway back the venture. This diverse investor base highlights broad confidence in EVERY's vision.
The investment targets several key areas. It will boost manufacturing capacity. It aims to accelerate the company's path to profitability. The funding will drive mass-market adoption. This includes both retail and foodservice channels.
EVERY's core innovation lies in precision fermentation. This advanced biomanufacturing process creates proteins. These proteins replicate traditional egg functionality. They offer a direct alternative to conventional eggs. The technology decouples protein production from animal agriculture. This provides a more sustainable and resilient food source.
The company's products offer critical advantages. They are animal-free. They are cage-free compliant. They eliminate exposure to livestock-related risks. Traditional egg production faces numerous vulnerabilities. These include disease outbreaks like avian flu. Volatile feed prices also create instability. Environmental concerns add to the pressure. EVERY's approach provides a robust solution.
A major milestone looms this month. EVERY Company proteins will launch in Walmart stores across the United States. This marks a pivotal moment. It shifts the company from niche offerings to mass-market availability. Walmart's vast distribution network offers unparalleled reach. This partnership will introduce animal-free egg proteins to millions of consumers.
EVERY’s product lineup includes OvoPro™ and OvoBoost™. OvoPro™ functions as a direct substitute for egg whites. OvoBoost™ is a neutral protein. It fortifies various food and beverage applications. These proteins are versatile. They integrate into baked goods, beverages, and protein supplements. Their applications span wide.
The proteins are available in powder form. This enhances logistical efficiency. They are shelf-stable for up to 18 months. This eliminates the need for refrigeration. It significantly reduces cold chain costs for manufacturers. This benefit is crucial for high-volume sectors like bakeries. Traditional liquid eggs demand costly cold storage and transport.
The global egg market is substantial. It represents $270 billion. EVERY seeks to secure a significant share. Its technology offers equivalent or superior functionality. It does so without the inherent risks of traditional supply chains. The company already produces metric tons of product monthly. It aims to meet demand from the world's largest food companies.
Food producers increasingly grapple with instability. Volatile egg prices are a constant challenge. Fragile supply chains often break down. Avian flu outbreaks devastate poultry populations. These factors highlight the urgent need for alternatives. EVERY provides a stable and reliable protein source. It frees producers from these systemic risks.
The company's technology is a game-changer. It offers functional, scalable solutions. It delivers large quantities of egg protein at commercial scale. This reassures food companies. They gain a reliable option for supply chain challenges. This demonstrates biomanufacturing's potential to transform the entire food industry.
EVERY's headquarters are in San Francisco. Its products are FDA-approved. This regulatory clearance underpins consumer trust. It also ensures broad market acceptance. The company is not just conceptualizing new ideas. It is delivering concrete, scalable solutions.
The investment supports increased production capacity. This is vital for the Walmart rollout. It ensures the company can meet soaring demand. Consumer interest in alternative proteins continues to rise. This trend is driven by health, ethical, and environmental considerations. EVERY is positioned to capitalize on this growing market.
Biomanufacturing is maturing rapidly. It is becoming a resilient, scalable part of the global food supply chain. EVERY Company stands at the forefront of this evolution. Its progress validates the sector's potential. It proves that next-generation food production is here. The future of food involves less reliance on animals. It embraces scientific innovation. EVERY leads this charge.